Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HL Tablet in NAFLD
NCT02491905Phase 2Completed
- Sponsor
- Huons
- Start
- Nov 2013
- Primary completion
- May 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ALS-L1023 in non-alcoholic fatty liver disease (NAFLD), sponsored by Huons. Started Nov 2013; status: completed.
02
Drugs
ALS-L1023
03
Conditions
non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT02491905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02491905.